Aaron Novikoff is a tenured postdoctoral researcher at Helmholtz Munich – Institute for Diabetes and Obesity. He earned his PhD in 2022 at Helmholtz Munich, where he investigated the molecular pharmacology of novel incretin receptor dual- and triple-agonists, as well as nuclear hormone-conjugated GLP-1 agonists, under the mentorship of Prof. Timo Müller and Prof. Matthias Tschöp. As a Helmholtz High Potential Fellow, his current research centers on novel peptide-based drug design, with an emphasis on harnessing subcellular dynamics and polypharmacology to enhance systemic therapeutic outcomes against diabetes and obesity.